Accretion Pharmaceuticals Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep '25 Sep 30, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Operating Revenue	825.48	573.76	133.53	293.84	222.92
Other Revenue	0.95	-	-	1.47	2.92
Revenue	826.43	573.76	133.53	295.32	225.84
Revenue Growth (YoY)	-	329.70%	-54.79%	30.76%	-
Cost of Revenue	601.95	400.22	94.36	240.11	179.93
Gross Profit	224.49	173.55	39.17	55.21	45.91
Selling, General & Admin	42.48	37.31	9.09	25.21	19.75
Other Operating Expenses	34.71	17.2	4.27	8.61	6.84
Operating Expenses	85.26	62.26	15.59	43.06	34.7
Operating Income	139.23	111.29	23.58	12.15	11.21
Interest Expense	-10.64	-13.87	-2.57	-10.25	-9.98
Currency Exchange Gain (Loss)	0.47	0.47	0.11	-	-
Other Non Operating Income (Expenses)	-0.25	-0.25	-1.17	-0.51	-0.19
Pretax Income	128.81	97.64	19.95	1.39	1.04
Income Tax Expense	38	29.7	5.02	0.35	0.25
Net Income	90.81	67.94	14.93	1.04	0.79
Net Income to Common	90.81	67.94	14.93	1.04	0.79
Net Income Growth	-	355.08%	1336.77%	31.52%	-
Shares Outstanding (Basic)	9	8	8	-	-
Shares Outstanding (Diluted)	9	8	8	-	-
Shares Change (YoY)	17.78%	5.47%	-	-	-
EPS (Basic)	9.82	8.48	1.96	-	-
EPS (Diluted)	9.82	8.48	1.96	-	-
EPS Growth	-	332.43%	-	-	-
Free Cash Flow	-	41.39	-169.87	-8.57	18.93
Free Cash Flow Per Share	-	5.16	-22.35	-	-
Gross Margin	27.16%	30.25%	29.33%	18.70%	20.33%
Operating Margin	16.85%	19.40%	17.66%	4.12%	4.96%
Profit Margin	10.99%	11.84%	11.18%	0.35%	0.35%
Free Cash Flow Margin	-	7.21%	-127.22%	-2.90%	8.38%
EBITDA	149.85	119.04	25.81	21.39	19.31
EBITDA Margin	18.13%	20.75%	19.33%	7.24%	8.55%
D&A For EBITDA	10.62	7.75	2.24	9.23	8.1
EBIT	139.23	111.29	23.58	12.15	11.21
EBIT Margin	16.85%	19.40%	17.66%	4.12%	4.96%
Effective Tax Rate	29.50%	30.42%	25.17%	25.14%	24.04%
Revenue as Reported	827.38	574.71	134.07	295.32	225.84
Advertising Expenses	-	0.17	-	0.16	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.